Company: BFRG
Filing Date: 2025-12-01
Form Type: 424B3
Source: 0001493152-25-025570
Chunk: 9

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-12-01
Form: 424B3
Chunk 9
---
 identify digital biomarkers from previous glufosfamide studies that serve as indicators of efficacy and safety performance for future decision-making; and (3) generate insights that inform Eleison’s clinical strategy for its additional investigational therapies, inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). Glufosfamide is a third-generation alkylating agent under evaluation in a pivotal Phase III international randomized trial for the treatment of second-line pancreatic cancer. This compound was designed to improve tumor-specific uptake while reducing systemic toxicity.

By integrating BullFrog’s proprietary platform into Eleison’s drug development process, the parties intend to generate deeper insights into patient safety and therapeutic response trends, thereby improving clinical trial execution and pipeline planning. The application of AI to cluster patients and extract digital biomarkers from existing data is expected to not only strengthen the glufosfamide development program but also accelerate the progression of Eleison’s broader oncology portfolio.

Sygnature Discovery Limited Joint Collaboration

On June 12, 2025, the Company entered into a strategic collaboration with Sygnature Discovery (“Sygnature”), a UK-based contract research organization specializing in drug discovery. Under this collaboration, Sygnature will introduce BullFrog Data Networks™, the Company’s proprietary AI-driven data insights platform powered by the bfLEAP™ engine, to Sygnature’s global biopharma client base.

| 5 |

BullFrog Data Networks™ is designed to facilitate the analysis of complex, multi-modal biomedical datasets, enabling the identification of novel biological pathways and disease mechanisms critical to drug discovery. The platform supports applications such as early target identification, mechanism-of-action elucidation, patient stratification, drug repurposing, and clinical trial optimization. Delivered through a user-friendly, disease-focused interface, BullFrog Data Networks™ aims to enable researchers to make informed and timely strategic decisions. Sygnature Discovery intends to leverage this platform to complement its existing drug discovery services and provide its clients with enhanced tools for data interpretation and target discovery, thereby improving research and development efficiency and success rates.

The collaboration establishes a joint marketing arrangement focused on the licensing and sale of BullFrog Data Networks™. Sygnature’s objectives include enhancing its service offerings through the partnership and actively promoting BullFrog’s product to customers engaged in target identification and clinical trial optimization projects. This collaboration positions BullFrog and Sygnature to accelerate innovation in drug discovery by combining advanced AI technology with expert research services, targeting diverse therapeutic